This appraisal was discussed by the technology appraisal committee on 13 May 2020.
The European Medicine's Agency's Committee for Medicinal Products for Human Use (CHMP) has not yet given its opinion on enzalutamide in this indication. We are therefore unable to issue an Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD) until a positive opinion is issued.